Damora Therapeutics, Inc.
DMRA Nasdaq
SEC CIK 1800315
Follow Damora Therapeutics
Weekly email: filings, results
Net income
−$32M
−921.1% vs same quarter last year
EPS, diluted
−$0.40
+83.1% vs same quarter last year
Operating cash flow
−$17.2M
−558.8% vs same quarter last year
Operating income
−$36.9M
−1068% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | - |
| FY24 | −$21.4M |
| FY23 | −$38.3M |
| FY22 | −$61.6M |
| FY21 | −$51.8M |
| FY20 | −$34.8M |
| FY19 | −$36.5M |
| FY18 | - |